机构：[1]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China临床科室肿瘤内科河北医科大学第四医院[2]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China医技科室病理科河北医科大学第四医院[3]Computer Network Information Center, Chinese Academy of Sciences, Beijing, 100190, China[4]ChosenMed Technology (Beijing) Co., Ltd., Beijing, 100176, China[5]University of the Chinese Academy of Sciences, Beijing, 100190, China
Little information is available regarding the therapeutic efficacy of immune checkpoint inhibitors and the prediction of DNA damage-repair (DDR) genes in mixed testicular germ-cell tumors (TGCTs). Here we report a pretreated patient with metastatic mixed TGCT harboring variations of three important DDR genes - BRCA2, MSH6 and PMS2 - identified by next-generation sequencing using plasma-based circulating tumor DNA. He obtained stable clinical benefit from PD-1 blockade. At the latest follow-up, he had a progression-free survival of more than 28 months and had survived 6.75 years since diagnosis. To our knowledge, this case is the first report of long-term clinical outcome obtained from immune checkpoint inhibitor therapy in a pretreated patient with mixed metastatic TGCT harboring co-mutations in DDR genes.
第一作者机构：[1]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China
通讯作者：
通讯机构：[1]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China
推荐引用方式(GB/T 7714)：
Zhang Hui,Jiang Da,Meng Erhong,et al.Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes[J].IMMUNOTHERAPY.2023,15(1):17-25.doi:10.2217/imt-2021-0259.
APA：
Zhang Hui,Jiang Da,Meng Erhong,Zhao Meng&Niu Beifang.(2023).Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes.IMMUNOTHERAPY,15,(1)
MLA：
Zhang Hui,et al."Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes".IMMUNOTHERAPY 15..1(2023):17-25
